Agenus Inc(AGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 2.6 | EPS (ttm) | 2.65 | Insider Own | 11.7% | Shs Outstand | 42.6M | Perf Week | -14.83% |
| Market Cap | 0.31B | Forward P/E | - | EPS next Y | -131.61% | Insider Trans | - | Shs Float | 39.8M | Perf Month | 0.88% |
| Enterprise Value | 0.57B | PEG | - | EPS next Q | -0.01 | Inst Own | 38.7% | Short Float | 14.75% | Perf Quarter | 124.43% |
| Income | 0.09B | P/S | 2.34 | EPS this Y | 140.79% | Inst Trans | 17.92% | Short Ratio | 1.38 | Perf Half Y | 108.16% |
| Sales | 0.13B | P/B | - | EPS next 5Y | 38.59% | ROA | 51.42% | Short Interest | 5.86M | Perf YTD | 119.43% |
| Book/sh | -4.67 | P/C | 16.55 | EPS past 3/5Y | 93.99% 82.55% | ROE | - | 52W High | -22.15% ($8.85) | Perf Year | 42.65% |
| Cash/sh | 0.42 | P/FCF | - | Sales past 3/5Y | 5.22% 5.31% | ROIC | - | 52W Low | 154.24% ($2.71) | Perf 3Y | -71.99% |
| Dividend Est. | - | EV/EBITDA | 14.16 | EPS Y/Y TTM | 138.02% | Gross Margin | 95.95% | Volatility(W/M) | 7.83% 7.69% | Perf 5Y | -94.6% |
| Dividend TTM | - | EV/Sales | 4.33 | Sales Y/Y TTM | 30.47% | Oper. Margin | 27.04% | ATR (14) | 0.6 | Perf 10Y | -94.26% |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | 98.53% | Profit Margin | 69.18% | RSI (14) | 44.8 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.34 | Sales Q/Q | 34.36% | SMA20 | -10.48% ($7.7) | Beta | 1.38 | Target Price | $19.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | 5.7% ($6.52) | Rel Volume | 0.21 | Prev Close | $6.86 |
| Employees | 81 | LT Debt/Eq | - | EPS/Sales Surpr. | -122.22% 1.47% | SMA200 | 61.37% ($4.27) | Avg Volume(3M) | 4.24M | Price | $6.89 |
| IPO | 2000/2/4 | Option/Short | Yes/Yes | Trades | 6684 | Volume | 890,699 | Change | 0.44% |
Company
AGEN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Agenus is a US clinical-stage biotech company focused on immuno-oncology. Building on its antibody-based immune checkpoint modulators and proprietary immune-enhancing (adjuvant) technology, the company is developing novel drug candidates targeting a range of solid tumors. Since its founding in 1994, Agenus has continued its research into cancer therapeutics leveraging immune mechanisms.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
AGEN has weak earning power
27.04% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +140.8% this year.
Tap to view numbers
The stock looks undervalued
Trading at 2.6 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -72.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 38.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
IWN 0.00%
IWO 0.00%
IWM 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $310M.
AGEN $310M PER 2.6
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is AGEN?
AGEN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AGEN?
The market cap of AGEN is approximately $310M, ranking 3,692 within its sector.
What is the P/E ratio of AGEN?
AGEN has a P/E ratio of approximately 2.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AGEN?
AGEN has recorded a 52-week high of $8.85 and a low of $2.71.
